Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

In this review, we discuss biomarkers of response and resistance to PI3K inhibitors (PI3Ki) in estrogen receptor-positive breast cancer, both in the early and advanced settings. We analyse data regarding PIK3CA mutations, PI3K pathway activation, PTEN expression loss, Akt signalling, insulin levels,...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandão, M, Caparica, R, Eiger, D, de Azambuja, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923785/
https://www.ncbi.nlm.nih.gov/pubmed/31859350
http://dx.doi.org/10.1093/annonc/mdz280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923785/
https://www.ncbi.nlm.nih.gov/pubmed/31859350
http://dx.doi.org/10.1093/annonc/mdz280

Ejemplares similares